Search results
Results from the WOW.Com Content Network
The rare simultaneous occurrence of thrombocytopenia (low blood platelets) with blood clots after vaccination raised the original concern about this condition. [citation needed] In many cases where acute thrombosis and thrombocytopenia have been found together after COVID‑19 vaccination, an antibody against platelet factor 4 has been ...
Why might some COVID-19 vaccines pose a small risk of blood clots while others don't? Scientists suspect it's related to their use of adenoviruses.
European Medicines Agency start 'review' of the safety of the COVID-19 Vaccine Janssen after reports that some patients who had received it had developed blood clots.
The diagnosis of Stevens–Johnson syndrome is based on involvement of less than 10% of the skin. [2] It is known as TEN when more than 30% of the skin is involved and considered an intermediate form when 10–30% is involved. [3] SJS/TEN reactions are believed to follow a type IV hypersensitivity mechanism. [7]
Johnson & Johnson's COVID-19 vaccine may pose a "small possible risk" of a rare but potentially dangerous neurological reaction, U.S. health officials said Monday.
This is a list of drugs and substances that are known or suspected to cause Stevens–Johnson syndrome This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources .
The blood clots in patients who received the J&J vaccine bear close resemblance to 169 cases in Europe reported with the AstraZeneca vaccine, out of 34 million doses administered there.
The Janssen COVID‑19 vaccine, (Ad26.COV2.S) sold under the brand name Jcovden, [1] is a COVID‑19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, [24] and its Belgian parent company Janssen Pharmaceuticals, [25] a subsidiary of American company Johnson & Johnson.